Insight

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

Collage of G Curigliano and Aditya Bardia

Oct 5, 2024, 09:20

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

ASCO shared a post on X:

“Experts Giuseppe Curigliano & Aditya Bardia discuss the results of the DESTINY-Breast06 trial, which showed significant PFS improvement with T-DXd in pts with HR+, HER2-low metastatic.”

DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?

Authors: Giuseppe Curiglian and Aditya Bardia

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

Source: ASCO/X

Aditya Bardia ASCO Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 fight against cancer Giuseppe Curigliano Global fight against cancer OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage